PALO ALTO, Calif., April 17 /PRNewswire-FirstCall/ -- Telik, Inc. , a biopharmaceutical company focused on discovering and developing drugs to treat serious diseases, today announced that it made four preclinical data presentations at the 99th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego, Calif. The abstracts highlighted results from Telik’s Research and Development programs.
Identification and Characterization of Novel Tyrosine Kinase Inhibitors Targeting Vascular Endothelial Growth Factor Receptor 2 [Abstract # 1439]
Mechanism of Induction of Apoptosis by TLK199 (TELINTRA(R)) in Human Leukemia Cell Lines [Abstract # 2270]
Identification of a Novel Class of Nonpeptidyl Small-Molecule Inhibitors of the Human Proteasome [Abstract # 3271]
Target-Related Affinity Profiling (TRAP(R)): Efficient Cancer Drug Discovery at Telik [Abstract # 4754]
Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced investigational drug candidates in clinical development are TELINTRA, a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates.
TELIK, the Telik logo, TELCYTA, TELINTRA and TRAP are trademarks or registered trademarks of Telik, Inc.
CONTACT: Patricia P. Frias, Corporate Communications of Telik, Inc.,
+1-650-845-7927, pfrias@telik.com
Web site: http://www.telik.com/
